European Parliament session

HTA session at the Parliament

Health Technology Assessment and Access to Innovative Oncology Drugs in Europe

European Cancer Patient Coalition


MEP Elisabetta Gardini

Tuesday, 25th September – 14:30 – 16:30

European Parliament, Room A5E-2

In light of the European Commission legislative proposal for future EU cooperation on Health Technology Assessment, the European Cancer Patient Coalition and Cancer Drug Development Forum is hosting a timely high-level discussion together with Elisabetta Gardini MEP. It will bring together stakeholders and policymakers to highlight the importance of a more harmonised approach to Health Technology Assessment for ensuring timely access to innovative oncology diagnostics and treatments. Innovative healthcare technologies offer the potential to improve the lives of many people living with cancer. Ensuring effective innovations are accessible and affordable to all patients is a challenge facing all cancer stakeholders. Very few HTA agencies in Europe involve patients in their assessments and, where public engagement is sought, the approached vary. The European Commission’s proposal seeks to dismantle barriers to involving patients in HTA, by creating established methods for providing patient evidence, but more robust patient engagement schemes are needed at both the EU and Member State levels.

Please read more on the webpage.

Register online:


14:30 Welcome
Elisabetta Gardini, Member of the European Parliament (EPP, Italy)

14:40 Setting the scene: Health Technology Assessment
Cristian-Silviu Buşoi, Member of the European Parliament (EPP, Romania)

14:50 ECPC achievements in HTA advocacy
Francesco De Lorenzo, President of the European Cancer Patient Coalition

15:00 Patient involvement in HTA in Member States
Martin Danner, Representative of Patient Organisations, Federal Joint Committee (G-BA), Germany

15:10 Member State Perspectives
Ortwin Schulte, Head of Unit “Health Policy”, Permanent Representation of Germany to the EU

15:20 Panel on Access to Innovation

Academic Perspective
Heinz Zwierzina, President, Cancer Drug Development Forum

Medical Oncologist Perspective
Paolo G. Casali, EU Policy Committee Chair, European Society for Medical Oncology

Industry Perspective
Ivana Cattaneo, Vice-Chair of the Oncology Platform, EFPIA

European Regulatory Perspective
Markus Paulmichl, Pharmacogenomics Working Party Vice-Chair, European Medicines Agency

15:50 – 16:15 Panel debate and Q&A with the audience

16:15 Closing remarks
Lieve Wierinck, Member of the European Parliament (ALDE, Belgium)